Related Experiment Videos
Genetic testing for familial hypercholesterolaemia: practical and ethical issues
S E Humphries1, D Galton, P Nicholls
1Department of Medicine, UCL Medical School, Rayne Institute, London, UK.
QJM : Monthly Journal of the Association of Physicians
|March 1, 1997
Summary
Genetic testing for familial hypercholesterolaemia (FH) aids in identifying individuals at high risk for early coronary artery disease (CAD). DNA tests are valuable for diagnosing FH and tracing mutations within families, especially in children.
Area of Science:
- Genetics and Cardiovascular Medicine
Background:
- Coronary artery disease (CAD) is influenced by genetics, environment, and comorbidities like diabetes and hypertension, complicating risk prediction.
- Familial hypercholesterolaemia (FH) significantly increases the risk of early CAD due to single-gene mutations.
Purpose of the Study:
- To summarize current knowledge on DNA-based tests for identifying and managing FH.
- To propose recommendations for genetic testing and future research in FH and CAD risk.
Main Methods:
- Review of current knowledge on DNA-based tests for FH.
- Formulation of recommendations for genetic testing and research priorities.
Main Results:
- DNA tests are most valuable for genetic tracing programs to identify and treat FH individuals.
- Genetic testing is appropriate for diagnosing FH in equivocal cases and detecting mutations in immediate family members, particularly children.
- Testing distant relatives for FH mutations is not currently recommended.
Conclusions:
- Genetic testing for FH is a key tool for early identification and management, especially in families with a history of premature CAD.
- Further research is needed to compare the clinical outcome prediction of genetic tests versus lipid levels for FH.
- Studies should evaluate the overall benefit of genetic testing for FH to patients, relatives, and healthcare systems.
Keywords:
Genetics and Reproduction